CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 123 filers reported holding CLOVIS ONCOLOGY INC in Q2 2016. The put-call ratio across all filers is 1.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,000 | -30.0% | 12,153 | +8.5% | 0.00% | – |
| Q2 2022 | $20,000 | -72.6% | 11,205 | -68.8% | 0.00% | – |
| Q1 2022 | $73,000 | -37.6% | 35,895 | -16.4% | 0.00% | – |
| Q4 2021 | $117,000 | -33.9% | 42,951 | +8.0% | 0.00% | – |
| Q3 2021 | $177,000 | -31.7% | 39,752 | -11.0% | 0.00% | -100.0% |
| Q2 2021 | $259,000 | +0.4% | 44,661 | +21.5% | 0.00% | 0.0% |
| Q1 2021 | $258,000 | +67.5% | 36,770 | +14.9% | 0.00% | 0.0% |
| Q4 2020 | $154,000 | +161.0% | 32,004 | +214.8% | 0.00% | – |
| Q3 2020 | $59,000 | -27.2% | 10,167 | -50.5% | 0.00% | – |
| Q3 2019 | $81,000 | -75.0% | 20,532 | -5.8% | 0.00% | -100.0% |
| Q2 2019 | $324,000 | -48.3% | 21,804 | -13.8% | 0.00% | -50.0% |
| Q1 2019 | $627,000 | +42.8% | 25,280 | +3.5% | 0.00% | +33.3% |
| Q4 2018 | $439,000 | -48.7% | 24,435 | -16.2% | 0.00% | -50.0% |
| Q3 2018 | $856,000 | -36.4% | 29,153 | -1.5% | 0.01% | -33.3% |
| Q2 2018 | $1,346,000 | -15.7% | 29,607 | -2.1% | 0.01% | -10.0% |
| Q1 2018 | $1,597,000 | -31.4% | 30,254 | -11.7% | 0.01% | -37.5% |
| Q4 2017 | $2,329,000 | -10.9% | 34,250 | +8.0% | 0.02% | -33.3% |
| Q3 2017 | $2,613,000 | +4.1% | 31,711 | +18.3% | 0.02% | -4.0% |
| Q2 2017 | $2,509,000 | +40.5% | 26,797 | -4.4% | 0.02% | +31.6% |
| Q1 2017 | $1,786,000 | +31.4% | 28,045 | -8.3% | 0.02% | +26.7% |
| Q4 2016 | $1,359,000 | +35.0% | 30,597 | +9.5% | 0.02% | +7.1% |
| Q3 2016 | $1,007,000 | +118.4% | 27,939 | -16.8% | 0.01% | +133.3% |
| Q2 2016 | $461,000 | -26.2% | 33,584 | +3.2% | 0.01% | -33.3% |
| Q1 2016 | $625,000 | -50.6% | 32,528 | -10.0% | 0.01% | -40.0% |
| Q4 2015 | $1,265,000 | -58.3% | 36,129 | +9.5% | 0.02% | -65.1% |
| Q3 2015 | $3,035,000 | +13.8% | 33,004 | +8.7% | 0.04% | +16.2% |
| Q2 2015 | $2,668,000 | +11.7% | 30,356 | -5.7% | 0.04% | +32.1% |
| Q1 2015 | $2,388,000 | +53.5% | 32,176 | +15.8% | 0.03% | +55.6% |
| Q4 2014 | $1,556,000 | +25.6% | 27,793 | +1.8% | 0.02% | +12.5% |
| Q3 2014 | $1,239,000 | -8.3% | 27,306 | -16.3% | 0.02% | -11.1% |
| Q2 2014 | $1,351,000 | -55.8% | 32,613 | -26.1% | 0.02% | -52.6% |
| Q1 2014 | $3,055,000 | +213.0% | 44,102 | +172.3% | 0.04% | +153.3% |
| Q4 2013 | $976,000 | -22.4% | 16,196 | -21.7% | 0.02% | -50.0% |
| Q3 2013 | $1,257,000 | +35.0% | 20,684 | +48.8% | 0.03% | +66.7% |
| Q2 2013 | $931,000 | – | 13,902 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |